Sun Pharmaceutical (SUNPHARMA.NS)

Executive Summary

Sun Pharmaceutical is a global specialty generic pharmaceutical company headquartered in Mumbai, India, with a presence in over 100 countries. The company's primary business involves the development, manufacturing, and marketing of a broad portfolio of generic and branded formulations, as well as active pharmaceutical ingredients (APIs). Sun Pharma has a research and development pipeline of 214 drug candidates, focusing on therapeutic areas such as cardiology, psychiatry, neurology, gastroenterology, diabetology, oncology, dermatology, and ophthalmology. Through its subsidiary Taro Pharmaceutical, it maintains a strong position in specialty segments. As a publicly traded entity, Sun Pharma's strategic direction is driven by its scale in generics and targeted investments in complex generics, specialty products, and novel drug delivery systems. The company's extensive pipeline and global footprint underpin its growth potential, though near-term catalysts are limited to regulatory approvals and data readouts from ongoing clinical trials.

Upcoming Catalysts (preview)

• 2027Data readout from Phase 2 trial of Garsorasib combination therapy in NSCLC40% success
• Q4 2026FDA approval for a complex generic product (e.g., generic testosterone or dermatological cream)70% success
• 2026Completion and potential results from Phase 3 nasopharyngeal carcinoma trial60% success